Arvinas Inc. (NASDAQ:ARVN) is one of the best small cap stocks with biggest upside potential. On August 8, Arvinas, in ...

Shares of the largest member of America's three-way telecom oligopoly last reached an all-time high in late 2019. The stock ...

Mixed options sentiment in Pfizer (PFE), with shares up 2c, or 0.1%, near $25.16. Options volume relatively light with 28k contracts traded and ...

Pfizer (NYSE: PFE) reported that its Phase III THRIVE-131 study of inclacumab, an experimental P-selectin inhibitor for ...

Let’s take a closer look at a few biotech stocks poised to benefit from this resurgence. Medicus Pharma Ltd. (NASDAQ: MDCX) is an emerging biotech and life sciences company with a global footprint ...

This is the latest hit for Pfizer’s sickle cell disease portfolio after pulling Oxbryta from the market in 2024.

Novo Nordisk A/S gains momentum with FDA approval for Wegovy and strategic pricing. Click for why Novo outshines Eli Lilly ...

Inclacumab, which Pfizer obtained in its 2022 acquisition of Global Blood Therapeutics, failed to significantly lower pain ...

The IVES AI 30 list is a group of 30 tech companies analysts led by Daniel Ives believe will define the future of the AI ...

Less than a year after it was forced to withdraw GBT's sickle cell disease (SCD) therapy Oxbryta from all world markets after ...

O’Reilly Auto Parts will become the title sponsor for NASCAR’s second-tier national series when the Xfinity Series is renamed ...

Pfizer set about evaluating inclacumab in pair of phase 3 studies, dubbed Thrive. The Big Pharma terminated one of those ...